fotemustine (Muphoran)

08/01/2002 - "Severe neurological disabilities after complete remission of advanced malignant melanoma following fotemustine therapy in combination with total brain irradiation."
06/01/2008 - "This study aimed to elucidate the potential inner-ear effects of fotemustine, a chemotherapeutic agent which crosses the blood-brain barrier and is used in the treatment of primary and metastatic brain tumours and metastatic melanoma. "
04/01/2001 - "In our study, we investigated the molecular mechanism of acquired resistance of melanoma cells (MeWo) to the chloroethylating drug fotemustine. "
03/01/1996 - "In this study, the authors identified seven-year survivors after completion of the French multicenter Phase II trial of fotemustine for the treatment of metastatic malignant melanoma. "
01/01/1994 - "Phase II trial of fotemustine in patients with metastatic malignant melanoma."

12/01/1992 - "It seems that fotemustine is superior to any other drug currently available in the treatment of these metastases."
01/01/1998 - "Phase I pharmacological study of intra-arterially infused fotemustine for colorectal liver metastases."
03/01/2014 - "We investigated prospectively the efficacy and toxicity of hepatic intra-arterial (HIA) versus systemic (IV) fotemustine in patients with liver metastases from UM. "
10/01/2002 - "Fotemustine is a nitrosourea that produced similar activity in CNS metastasis as in systemic disease, with a response rate of about 25%. "
12/01/1992 - "Metastases were classified according to their size: < or = 1 cm (group A), 1.1-4 cm (group B), and > 4 cm (group C), in order to assess the clinical course of the disease and predict the response to treatment with fotemustine. "

03/01/1999 - "Therefore, fotemustine seems to represent an interesting well-tolerated treatment possibility in patients with inoperable recurrent malignant gliomas of the brain."
01/01/2014 - "We reviewed the most important studies on fotemustine treatment in glioma patients analyzing its pharmacological profile and its activity and safety. "
11/01/2010 - "Low-dose fotemustine for recurrent malignant glioma: a multicenter phase II study."
04/01/2001 - "This combined regimen of PCZ and fotemustine was well tolerated with a good disease control rate in heavily pretreated glioma patients and merits further investigation in phase II studies."
03/01/1995 - "Fotemustine in patients with relapsing malignant gliomas - a phase-ii trial."

05/01/2011 - "In the present study we investigated the feasibility and effectiveness of a new biweekly schedule of fotemustine (FTM) in patients with recurrent glioblastoma, after at least one previous treatment. "
07/01/2013 - "Efficacy and safety of second-line fotemustine in elderly patients with recurrent glioblastoma."
11/01/2010 - "Can high-dose fotemustine reverse MGMT resistance in glioblastoma multiforme?"
10/01/2009 - "Fotemustine and recurrent glioblastoma: possible new opportunities for an old drug."
03/01/2009 - "Fotemustine was safe and effective as second-line chemotherapy in recurrent glioblastoma."

03/01/1996 - "Pharmacokinetics and pharmacodynamics of nitrosourea fotemustine: a French cancer centre multicentric study."
01/01/1989 - "[Study of the clinical pharmacokinetics of fotemustine in various tumor indications]."
09/01/2009 - "Fotemustine is a cancer chemotherapeutic agent that belongs to an extremely active class of alkylating compounds. "
03/01/1993 - "It is concluded that fotemustine should be regarded as having clear potential to induce cancer in humans. "
06/01/2009 - "Adjuvant chemotherapy, fotemustine, was administered at tumor progression as standard and classic regimen. "